The event highlighted the scientific rationale and preclinical data supporting allosteric, pan-mutant selective PI3Kα inhibitors for cancer and vascular anomalies. OKI-345 and OKI-355 show high selectivity and efficacy, with INDs planned for 2027 and a focus on safety and patient adherence.

Based on

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.